Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,276.00
Bid: 12,272.00
Ask: 12,278.00
Change: 12.00 (0.10%)
Spread: 6.00 (0.049%)
Open: 12,268.00
High: 12,312.00
Low: 12,258.00
Prev. Close: 12,264.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

Thu, 08th Feb 2024 12:08

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

At the top of the FTSE 100 index on Thursday at midday was DS Smith, after announcing Mondi approached the firm with a GBP10 billion packaging tie-up.

The FTSE 100 index edged down 8.93 points, 0.1%, at 7,619.82. The FTSE 250 was up 83.54 points, 0.4%, at 19,188.07, and the AIM All-Share was up 2.11 points, 0.3%, at 753.57.

The Cboe UK 100 was down 0.1% at 762.32, the Cboe UK 250 was up 0.6% at 16,619.76, and the Cboe Small Companies was down 0.4% at 14,578.09.

In European equities on Thursday, the CAC 40 in Paris was up 0.4%, while the DAX 40 in Frankfurt was flat.

Two US Federal Reserve officials indicated Wednesday that the nation's central bank is on track to tackle inflation, but that it is still too soon to begin lowering interest rates.

"We have a labour market that is at historic levels of strength," Richmond Fed President Tom Barkin told an event in the city.

"Job gains, unemployment, job openings, initial jobless claims, all of these metrics are very strong and inflation is coming down," he said. "So I'm very supportive of being patient, you know, to get to where we need to get."

Speaking earlier the same day, Fed Governor Adriana Kugler also indicated she believed the US central bank should pause for a little longer before acting on interest rates.

"At some point, the continued cooling of inflation and labour markets may make it appropriate to reduce the target range for the federal funds rate," she said.

Ipek Ozkardeskaya, senior analyst at Swissquote Bank, commented: "But knowing that the Fed is done hiking its rates and the expectation that the next move from the Fed will be a rate cut is enough to keep the market in a sweet spot. A delay in the timing of the first rate cut is even perceived as a good thing: the US economy is doing so well that there is no urge to cut the rates right away."

The pound was quoted at USD1.2608 at midday on Thursday in London, lower compared to USD1.2623 at the equities close on Wednesday. The euro stood at USD1.0767, flat against USD1.0765. Against the yen, the dollar was trading at JPY149.11, up compared to JPY148.01.

In the FTSE 100, DS Smith shares shot up 11%, while shares in Mondi were down 1.8%.

DS Smith said it has received a "highly preliminary expression of interest" from packaging industry peer Mondi about a possible merger, which would create a company worth more than GBP10 billion.

"The board of DS Smith understands that Mondi is considering a possible offer for DS Smith although no proposal has been received at this stage," DS Smith said.

It noted the put-up-or-shut-up deadline for Mondi under UK takeover rules will be March 7.

As far back as early 2021, Bloomberg had reported that Mondi was considering a tilt at DS Smith, citing at the time "people familiar with the matter". Nothing came of it at that time.

British American Tobacco shares surged 6.9% higher.

The London-based maker of cigarettes and vapes said revenue fell 1.3% to GBP27.28 billion in 2023 from GBP27.66 billion in 2022. The company swung to a pretax loss of GBP17.06 billion from a profit of GBP9.32 billion a year prior.

BAT declared a total dividend of 235.52 pence per share for 2023, up 2.0% from 230.9p a year prior.

Looking ahead, Chief Executive Tadeu Marroco said: "We are investing to strengthen our US business, accelerate innovation momentum, and enhance capabilities that support our strategic delivery. We expect these investments, together with the US macro-economic pressures, will impact 2024. Thereafter, we will progressively build to deliver 3-5% organic revenue, and mid-single digit adjusted organic profit from operations growth by 2026 on a constant currency basis. We are committed to continuing to reward shareholders with strong cash returns throughout this period."

Meanwhile, AstraZeneca was the worst performer on the index, falling 4.5%.

For 2023, the Cambridge, England-based pharmaceutical company's revenue rose to USD45.81 billion from USD44.35 billion and pretax profit more than doubled to USD6.90 billion from USD2.50 billion.

"Many investors view AstraZeneca as invincible given its success in recent years, yet its latest results showed that even the mighty can disappoint. The drugs giant missed fourth quarter earnings expectations due to more money being spent on research and development and a greater contribution from lower-margin sales in emerging markets. However, the business remains optimistic about the prospects for its cancer and rare disease drugs," AJ Bell analyst Russ Mould commented.

In the FTSE 250, Watches of Switzerland was 1.9% higher.

The Leicester, England-based watch retailer, whose key brands include Rolex, Cartier and Patek Phillipe said that in the 13 weeks to January 28, its financial third quarter, revenue fell 2.5% to GBP397 million from GBP407 million a year earlier.

Watches noted that "trading in the run-up to and beyond Christmas was tougher than originally expected, particularly in the UK amidst slower demand for luxury discretionary purchases".

The company added that trading conditions experienced in the third quarter of financial 2024 in the UK and US are expected to continue over the remainder of the fiscal year.

Amongst London's small-caps, Digital 9 shares toppled 16%.

Back in November, the investor had announced the sale of its stake in the Verne Group for up to USD575 million. The disposal of the data group to funds managed by Ardian France SA comprises USD440 million in cash, split between USD415 million payable on closure of the deal and deferred consideration of USD25 million.

On Thursday, Digital 9 said the Icelandic antitrust authority, the body responsible for providing the Icelandic regulatory approval, has decided to open a phase 2 investigation into the Verne transaction.

"Under the relevant applicable law, the period for the Phase II investigation is up to 90 working days which can be extended to 125 working days. The Icelandic anti-trust authority is not obliged to use the full period to conclude its review," Digital 9 said.

Stocks in New York were called lower. The Dow Jones Industrial Average, the S&P 500 index, and the Nasdaq Composite are all called down 0.2%.

Brent oil was quoted at USD79.94 a barrel at midday in London on Thursday, up from USD78.98 late Wednesday. Gold was quoted at USD2,029.99 an ounce, lower against USD2,039.13.

Still to come on Thursday's economic calendar, there is the weekly US initial jobless claims reading at 1330 GMT.

By Sophie Rose, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
8 May 2024 19:10

Sector movers: Aerospace and Defence, Pharma pace gains

(Sharecast News) - London's main stock market gauges continued to push higher in the middle of the week, even as investors waited on the Bank of England's policy announcement on the following day.

Read more
8 May 2024 17:46

FTSE 100 hits record high, pound slips ahead of BoE verdict

FTSE 100 up 0.5%, FTSE 250 adds 0.4%

*

Read more
8 May 2024 16:36

London close: Stocks rise further ahead of BoE decision

(Sharecast News) - London's stock markets closed with gains on Wednesday, bolstered by a dip in the value of the pound against both the dollar and the euro.

Read more
8 May 2024 09:44

AstraZeneca says withdraws Covid vaccine "for commercial reasons"

(Alliance News) - Drugmaker AstraZeneca PLC said Wednesday that it has withdrawn its Covid vaccine Vaxzevria, one of the first produced in the pandemic, citing "commercial reasons" and a surplus of updated jabs.

Read more
8 May 2024 09:39

LONDON BROKER RATINGS: UBS raises Centrica to 'buy' from 'neutral

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:

Read more
7 May 2024 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
7 May 2024 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.